$KRTL KRTL Biotech Spotlights Anti-Infectives and Antibiotics Portfolio to Support Public Health and Global Treatment Access
https://www.globenewswire.com/news-release/20...ccess.html
Lakewood, CO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its majority-owned subsidiary, KRTL Biotech, Inc., is highlighting its expanded portfolio of anti-infective and antibiotic products, developed in collaboration with SIGMA Corp., as part of the Company’s broader initiative to strengthen access to essential medicines in underserved and emerging healthcare markets.
The anti-infectives product line currently includes targeted, essential formulations such as:
Hostess Suspension (Trimethoprim + Sulfamethoxazole) – Broad-spectrum bactericidal
Positrin (Erythromycin Ethylsuccinate) – Macrolide antibiotic
Taxonid (Nitazoxanide) – Broad-spectrum antiparasitic
While the current portfolio is focused, SIGMA’s GMP-certified facility enables the production of a broader range of anti-infective therapies, including:
Penicillin derivatives (e.g., amoxicillin)
Macrolides and fluoroquinolones (e.g., azithromycin
Oral suspensions and pediatric antibiotics
Injectables for inpatient and outpatient treatment
These existing and potential offerings are aligned with the World Health Organization’s (WHO) Model List of Essential Medicines, reinforcing KRTL Biotech’s strategy to meet critical public health needs in both regional and global markets.
According to recent industry research, the global anti-infectives market—including antibiotics, antiparasitics, and related formulations—is estimated to exceed $150 billion annually. Much of this demand is driven by institutional purchasing, national health programs, and urgent care infrastructure in both developed and emerging economies.
With vertically integrated operations in South America and streamlined logistics through its SIGMA facility in Cochabamba, KRTL Biotech is strategically positioned to compete on both cost and quality. The Company's scalable operations—certified under internationally recognized Good Manufacturing Practices (GMP)—enable efficient production with competitive pricing, strong quality control, and regional proximity to key LATAM and global markets. This combination of operational efficiency and regulatory alignment enables KRTL Biotech to deliver measurable value to public health systems, procurement agencies, and commercial partners seeking reliable anti-infective sourcing solutions.
"Access to reliable anti-infectives is vital to global public health, especially as resistance trends continue to rise," said Daniel Bishop, CEO of KRTL Biotech. "Our formulations are trusted in real-world settings, and we’re now exploring avenues to expand those capabilities internationally."
All anti-infective products are manufactured at SIGMA’s facility in Cochabamba, Bolivia, which operates in accordance with internationally recognized GMP standards to ensure product integrity, safety, and consistency. KRTL Biotech is currently evaluating regulatory pathways for select formulations to enter U.S. and other export markets, including ANDA submissions, OTC eligibility, and international approvals aligned with regional procurement standards.
"We are proud that our anti-infective line plays a crucial role in public health programs here in Bolivia," said Patricia Wilstermann, CEO of SIGMA Corp. "Through our partnership with KRTL, we’re building toward an international framework that extends this impact across borders."
In fiscal year 2024, SIGMA’s anti-infective and antibiotic products represented a significant portion of its national pharmaceutical distribution in Bolivia, contributing notably to hospital and public health system supply chains. This operational foundation reinforces KRTL Biotech’s confidence in scaling this category to meet international needs.
"This product class exemplifies how public health value and commercial readiness can align," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Anti-infectives remain one of the most essential and scalable pharmaceutical segments, and KRTL is positioned to responsibly support that demand."
https://www.globenewswire.com/news-release/20...ccess.html
Lakewood, CO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its majority-owned subsidiary, KRTL Biotech, Inc., is highlighting its expanded portfolio of anti-infective and antibiotic products, developed in collaboration with SIGMA Corp., as part of the Company’s broader initiative to strengthen access to essential medicines in underserved and emerging healthcare markets. The anti-infectives product line currently includes targeted, essential formulations such as:
Hostess Suspension (Trimethoprim + Sulfamethoxazole) – Broad-spectrum bactericidal
Positrin (Erythromycin Ethylsuccinate) – Macrolide antibiotic
Taxonid (Nitazoxanide) – Broad-spectrum antiparasitic
While the current portfolio is focused, SIGMA’s GMP-certified facility enables the production of a broader range of anti-infective therapies, including:
Penicillin derivatives (e.g., amoxicillin)
Macrolides and fluoroquinolones (e.g., azithromycin
Oral suspensions and pediatric antibiotics
Injectables for inpatient and outpatient treatment
These existing and potential offerings are aligned with the World Health Organization’s (WHO) Model List of Essential Medicines, reinforcing KRTL Biotech’s strategy to meet critical public health needs in both regional and global markets.
According to recent industry research, the global anti-infectives market—including antibiotics, antiparasitics, and related formulations—is estimated to exceed $150 billion annually. Much of this demand is driven by institutional purchasing, national health programs, and urgent care infrastructure in both developed and emerging economies.
With vertically integrated operations in South America and streamlined logistics through its SIGMA facility in Cochabamba, KRTL Biotech is strategically positioned to compete on both cost and quality. The Company's scalable operations—certified under internationally recognized Good Manufacturing Practices (GMP)—enable efficient production with competitive pricing, strong quality control, and regional proximity to key LATAM and global markets. This combination of operational efficiency and regulatory alignment enables KRTL Biotech to deliver measurable value to public health systems, procurement agencies, and commercial partners seeking reliable anti-infective sourcing solutions.
"Access to reliable anti-infectives is vital to global public health, especially as resistance trends continue to rise," said Daniel Bishop, CEO of KRTL Biotech. "Our formulations are trusted in real-world settings, and we’re now exploring avenues to expand those capabilities internationally."
All anti-infective products are manufactured at SIGMA’s facility in Cochabamba, Bolivia, which operates in accordance with internationally recognized GMP standards to ensure product integrity, safety, and consistency. KRTL Biotech is currently evaluating regulatory pathways for select formulations to enter U.S. and other export markets, including ANDA submissions, OTC eligibility, and international approvals aligned with regional procurement standards.
"We are proud that our anti-infective line plays a crucial role in public health programs here in Bolivia," said Patricia Wilstermann, CEO of SIGMA Corp. "Through our partnership with KRTL, we’re building toward an international framework that extends this impact across borders."
In fiscal year 2024, SIGMA’s anti-infective and antibiotic products represented a significant portion of its national pharmaceutical distribution in Bolivia, contributing notably to hospital and public health system supply chains. This operational foundation reinforces KRTL Biotech’s confidence in scaling this category to meet international needs.
"This product class exemplifies how public health value and commercial readiness can align," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Anti-infectives remain one of the most essential and scalable pharmaceutical segments, and KRTL is positioned to responsibly support that demand."
